Comparison of transperineal and transrectal biopsy approaches to detect clinically significant prostate cancer in patients undergoing MRI fusion prostate biopsy: A lesion level analysis.

Authors

null

Andrew Wood

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH

Andrew Wood , Prajit Khooblall , Tarik Benidir , Jennifer Bullen , Ryan Ward , Andrei Purysko , Christopher J. Weight

Organizations

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, Cleveland Clinic, Cleveland, OH

Research Funding

No funding received
None.

Background: The use of transperineal (TP) prostate biopsy has gained in popularity due to reduced risk of infectious events, however evidence regarding cancer detection rates versus transrectal (TR) prostate biopsy is lacking. Our objective was to examine whether transperineal (TP) MRI-fusion targeted prostate biopsy (MRI-TBx) resulted in improved detection of clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology (ISUP) grade group ≥2, as compared to TR MRI-TBx. Methods: Retrospective review of all patients who underwent MRI-TBx at a tertiary care academic center. A cohort of patients who underwent TP MRI-TBx was compared to a second cohort of patients who underwent TR MRI-TBx. The primary outcome of interest was detection of csPCa, however detection of ISUP grade group 1 prostate cancer (GG1 PCa) was also examined. Analyses were performed on a lesion level basis. Multivariable logistic regression analyses were performed to assess for predictors of csPCa detection. Results: A total of 389 and 1144 lesions from 303 and 836 patients who underwent TP MRI-TBx vs TR MRI-TBx respectively were included in the analysis. The detection of both csPCa (39.6% vs 29.6%, p <0.001) and GG1 PCa (34.4% vs 21.1%, p <0.001) was higher for TP MRI-TBx vs. TR MRI-TBx. On multivariable analysis adjusted for age, prior biopsy status, Prostate Imaging–Reporting and Data System (PIRADS) score, prostate volume, PSA, size of PIRADS lesion, and zone of PIRADS lesion, TP MRI-TBx remained an independent predictor of csPCa (odds ratio [OR] 1.49, 95% CI 1.13-1.98). Surprisingly, transperineal biopsy was not a significant predictor of csPCa for Transition zone lesions (OR 1.24, p = 0.35), but was for Peripheral zone lesions (OR = 1.84, p < 0.001). Conclusions: Performance of TP MRI-TBx demonstrates improved detection of both csPCa and GG1 PCa. This difference is not dependent on anterior/transition zone location. This has important implications in risk assessment for localized prostate cancer, including counseling for active surveillance and definitive management strategies.

TransperinealTransrectalp-value
Number of lesions3891144
Mean Age (years)67.265.90.005
Mean PSA (ng/mL)8.259.20NS
Mean Prostate Volume (mL)49.753.0NS
Prior Biopsy Status (%)
- Biopsy naïve
- AS
- Prior negative

155 (39.8%)
139 (35.7%)
95 (24.4%)

726 (63.9%)
315 (27.7%)
96 (8.44%)
<0.001
PIRADSv2.0 score (%)
- PIRADS 3
- PIRADS 4
- PIRADS 5

90 (23.1%)
194 (49.9%)
105 (27.0%)

294 (25.9%)
582 (51.2%)
261 (23.0%)
NS
Prostate Zone (%)
- Peripheral
- Transition
- Central

241 (62.0%)
148 (38.0%)
0

772 (70.2%)
310 (28.2%)
18 (1.6%)
<0.001
csPCa (%)154 (39.6%)336 (29.6%)<0.001
GG1 PCa (%)134 (34.4%)240 (21.1%)<0.001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Diagnostics and Imaging

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 320)

DOI

10.1200/JCO.2023.41.6_suppl.320

Abstract #

320

Poster Bd #

K18

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

Racial differences in the utilization of MRI-guided biopsy before prostate cancer diagnosis.

First Author: Grace L. Lu-Yao

Abstract

2023 ASCO Genitourinary Cancers Symposium

Prediction of significant prostate cancer in equivocal MRI lesions: A high-volume international multicenter study.

First Author: August Sigle

First Author: Thorgerdur Palsdottir

First Author: Maxwell Sandberg